Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod

OBJECTIVES: To evaluate whether a third vaccination shows an added effect on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple sclerosis treated with ocrelizumab or fingolimod. METHODS: This is a substudy of a prospective multicenter study on SAR...

Descripción completa

Detalles Bibliográficos
Autores principales: Palomares Cabeza, Virginia, Kummer, Laura Y.L., Wieske, Luuk, Hagen, Ruth R., Duurland, Mariel, Konijn, Veronique A.L., van Dam, Koos P.J., Stalman, Eileen W., van de Sandt, Carolien E., Boekel, Laura, Verstegen, Niels J.M., Steenhuis, Maurice, Rispens, Theo, Tas, Sander W., Wolbink, Gertjan, Killestein, Joep, Kuijpers, Taco W., van Ham, S. Marieke, Eftimov, Filip, Brinke, Anja ten, van Kempen, Zoé L.E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical/Scientific Note
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082763/
https://www.ncbi.nlm.nih.gov/pubmed/35523569
http://dx.doi.org/10.1212/NXI.0000000000001178

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9082763/
https://www.ncbi.nlm.nih.gov/pubmed/35523569
http://dx.doi.org/10.1212/NXI.0000000000001178

Ejemplares similares